Methods for rapid multiplex HLA genotyping and transcript quantitation
Summary
The USPTO has published a new patent application detailing methods for rapid multiplex HLA genotyping and transcript quantitation using nanopore technology. The application, assigned to The University of North Carolina at Chapel Hill, outlines techniques for determining HLA status and genotyping donor cells for transplantation.
What changed
This document is a USPTO patent application (US20260085348A1) for methods of rapid multiplex HLA genotyping and transcript quantitation. The disclosed methods involve processing mRNA from HLA gene products, reverse transcribing it to cDNA, amplifying HLA-specific cDNAs, and sequencing them to determine the HLA status of a subject or to genotype donor cells for transplantation. The application specifically mentions identifying the presence or absence of HLA-A, -B, -C, -DRB 1/3/4/5, -DQA1, and -DQB1.
As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signifies potential future technological advancements in diagnostics and transplantation. Companies involved in molecular diagnostics, genetic testing, and organ transplantation may find this technology relevant for R&D and future product development. No penalties are associated with patent applications themselves; they represent claims to intellectual property.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
UNIQUE MOLECULAR IDENTIFIER ENHANCED HLA GENOTYPING AND TRANSCRIPT QUANTITATION USING NANOPORE TECHNOLOGY
Application US20260085348A1 Kind: A1 Mar 26, 2026
Assignee
The University of North Carolina at Chapel Hill
Inventors
Eric Thomas Weimer, Maureen C. Montgomery
Abstract
Provided are methods for rapid multiplex HLA genotyping and transcript quantitation. In some embodiments, the presently disclosed methods include providing a. sample from the cell, tissue, or organ that has mRNA derived from an HLA gene product; reverse transcribing the mRNA to produce a. pool of cDNAs; amplifying the cDNAs that result from reverse transcription of HLA-specific mRNAs to produce a pool of HLA-specific cDNAs; and determining the sequence of each HLA-specific cDNAs, whereby the HLA status of the cell, tissue, organ, or subject is determined. Also provided are methods for genotyping donor cells, tissues, and/or organs meant for transplantation into recipients. In some embodiments, the methods can be used to identify the presence of absence of each of HLA-A, -B, -C, -DRB 1/3/4/5, -DQA1, and -DQB1 in a biological sample.
CPC Classifications
C12Q 1/6869 C12N 15/1096 C12Q 1/6806 C12Q 1/6881 C12Q 2600/158
Filing Date
2023-05-18
Application No.
18866905
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.